Novoprotein(SH:688137) Zheng Quan Zhi Xing·2025-08-27 11:24Core Points - The company has prepared a special report on the use of raised funds for the first half of 2025, ensuring compliance with relevant regulations and confirming the accuracy of the report [1][2][5] Fundraising Overview - The company raised a total of RMB 1,754.386 million by issuing 17.54 million shares at a price of RMB 106.19 per share, with the total expected fundraising amount being RMB 1,754.386 million [1] - As of June 30, 2025, the cumulative investment of raised funds amounted to RMB 429.0863 million, with interest income received totaling RMB 91.1389 million and bank fees paid of RMB 0.0066 million, leaving a balance of RMB 1,404.2419 million [1][2] Fund Management - The company has established a fundraising management method to regulate the storage, approval, use, management, and supervision of raised funds, ensuring investor protection [2] - A tripartite supervision agreement has been signed with various banks to manage the special account for raised funds, with a balance of RMB 659.9814 million as of June 30, 2025 [2][3] Actual Use of Funds - As of June 30, 2025, the company has not used idle raised funds to temporarily supplement working capital [3] - The company has approved the use of idle raised funds for cash management, allowing for investments in safe and liquid products up to RMB 1 billion, with a total of RMB 744.2187 million in large transferable certificates of deposit as of June 30, 2025 [3][5] Other Fund Usage - The company has initiated a share repurchase plan using part of the raised funds, with a total repurchase amount between RMB 10 million and RMB 20 million, and has repurchased 404,337 shares for a total of RMB 11.9598 million as of June 30, 2025 [5][6] - There have been no changes in the direction of the raised funds or issues in the use and disclosure of the funds as of June 30, 2025 [5][6]